Table 2.
Comparison of clinical characteristics, laboratory parameters, and polysomnographic parameters in OSA patients with NAFLD and without NAFLD in OSA
| With NAFLD | Without NAFLD | p | |
|---|---|---|---|
| N (%) | 276 (74.19%) | 96 (25.81%) | |
| Age (years) | 48.97 ± 11.89 | 48.94 ± 18.98 | 0.174 |
| Male sex, number (%) | 229 (82.97%) | 74 (77.08%) | 0.337 |
| Antilipimic agents (%) | 5.3% | 4.4% | 0.868 |
| Antidiabetic agents (%) | 8.6% | 4.7% | 0.002 |
| Antihypertensive agents (%) | 28.2% | 9.3% | 0.010 |
| BMI (kg/m2) | 27.85 ± 6.66 | 25.35 ± 3.53 | 0.000 |
| Neck circumference (cm) | 38.50 ± 9.06 | 36.66 ± 8.84 | 0.081 |
| Waist circumference (cm) | 94.46 ± 22.26 | 88.94 ± 21.00 | 0.033 |
| AHI | 41.48 ± 23.30 | 33.78 ± 21.34 | 0.004 |
| ODI | 34.59 ± 24.00 | 26.44 ± 21.77 | 0.004 |
| TS90% | 9.64 ± 15.51 | 8.49 ± 22.39 | 0.580 |
| LaSO2 (%) | 70.42 ± 14.26 | 76.07 ± 12.59 | 0.000 |
| mean SpO2 (%) | 91.45 ± 7.30 | 92.91 ± 4.30 | 0.068 |
| ESS score | 9.08 ± 5.96 | 8.91 ± 5.68 | 0.804 |
| HbA1c (%) | 3.03 ± 3.24 | 1.52 ± 2.64 | 0.000 |
| Fasting glucose (mmol/L) | 5.58 ± 1.87 | 4.79 ± 1.35 | 0.000 |
| Insulin (mmol/L) | 73.76 ± 85.18 | 47.16 ± 47.45 | 0.000 |
| TC (mmol/L) | 5.14 ± 1.87 | 4.48 ± 1.53 | 0.182 |
| TG (mmol/L) | 3.53 ± 1.96 | 1.53 ± 1.30 | 0.369 |
| LDL-c (mmol/L) | 3.12 ± 1.18 | 2.85 ± 1.15 | 0.055 |
| HDL-c (mmol/L) | 1.09 ± 0.64 | 1.12 ± 0.43 | 0.674 |
| HOMA-IR | 3.78 ± 3.35 | 2.42 ± 1.57 | 0.000 |
| AST (U/L) | 21.56 ± 7.75 | 26.05 ± 20.92 | 0.174 |
| ALT (U/L) | 20.66 ± 12.10 | 35.34 ± 30.15 | 0.000 |
OSA, obstructive sleep apnea; BMI, body mass index; AHI, apnea-hypopnea index; ODI, oxygen desaturation index; T90%, the percentage of total sleep time spent with SpO2 < 90%; LaSO2, lowest O2 saturation; ESS score, Epworth Sleepiness Scale score; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein-cholesterol; LDL-C low-density lipoprotein-cholesterol; ALT, alanine aminotransferase; AST, aspartate aminotransferase
*p < 0.05